Cell Signaling Technology, Inc.
Records under this name other than the patents Cell Signaling Technology, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 38 patents it holds.
Back to Cell Signaling Technology, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,208,125 | Anti-Mucin 1 Binding Agents and Uses Thereof now held by University of Pittsburgh - of the Commonwealth System of Higher Education - of the Commonwealth System of Higher Education In force · High confidence | In force | High confidence | |
| US 11,428,696 | Mass Spectrometry Analysis of Mutant Polypeptides in Biological Samples Lapsed on the fee record Ended Aug 30, 2026 · High confidence | Lapsed on the fee record | Ended Aug 30, 2026 | High confidence |
| US 7,932,044 | Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing Pdgfr-Alpha Term ended Term ended Jul 1, 2025 · High confidence | Term ended | Term ended Jul 1, 2025 | High confidence |
| US 8,466,160 | Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-ALPHA Term ended Term ended Jul 1, 2025 · High confidence | Term ended | Term ended Jul 1, 2025 | High confidence |
| US 7,105,642 | Monoclonal Antibodies Specific for Phosphorylated Estrogen Receptor Alpha (SER118) and Uses Thereof Term ended Term ended May 28, 2024 · High confidence | Term ended | Term ended May 28, 2024 | High confidence |
| US 7,183,385 | Phospho-Specific Antibodies to FLT3 and Uses Thereof Term ended Term ended Apr 23, 2024 · High confidence | Term ended | Term ended Apr 23, 2024 | High confidence |
| US 8,512,967 | Method for Predicting the Response to HER2-DIRECTED Therapy now held by Ventana Medical Systems, Inc. Term ended Term ended Apr 7, 2023 · High confidence | Term ended | Term ended Apr 7, 2023 | High confidence |
| US 8,956,822 | Method for Predicting the Response to HER2-DIRECTED Therapy now held by Ventana Medical Systems, Inc. Term ended Term ended Apr 7, 2023 · High confidence | Term ended | Term ended Apr 7, 2023 | High confidence |
| US 9,239,331 | Method for Predicting the Response to HER2-DIRECTED Therapy now held by Ventana Medical Systems, Inc. Term ended Term ended Apr 7, 2023 · High confidence | Term ended | Term ended Apr 7, 2023 | High confidence |
| US 7,344,714 | Production of Motif-Specific and Context-Independent Antibodies Using Peptide Libraries as Antigens Term ended Ended no later than Dec 24, 2020 · Low confidence | Term ended | Ended no later than Dec 24, 2020 | Low confidence |